7:01 AM ET
8-K
Other 8-K Filing
Foghorn Therapeutics Other 8-K Filing
Foghorn Therapeutics and Eli Lilly have decided to discontinue the clinical development of FHD-909 and their SMARCA2 degrader collaboration following a review of Phase 1 data. Consequently, Foghorn is implementing a strategic reprioritization and a 40% workforce reduction to extend its cash runway into the second half of 2029, incurring approximately $2.3 million in severance-related charges.
- Counterparty
- Eli Lilly and Company